Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
103,249,738
-
Shares change
-
-2,622,293
-
Total reported value, excl. options
-
$289,096,531
-
Value change
-
-$2,381,228
-
Put/Call ratio
-
76%
-
Number of buys
-
54
-
Number of sells
-
-83
-
Price
-
$2.80
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2020
177 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2020.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 103,249,738 shares
of 236,234,693 outstanding shares and own 44% of the company stock.
Largest 10 shareholders include STATE STREET CORP (22,476,534 shares), WELLINGTON MANAGEMENT GROUP LLP (12,590,463 shares), BlackRock Inc. (11,397,548 shares), VANGUARD GROUP INC (8,434,759 shares), Nantahala Capital Management, LLC (7,040,487 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), GOLDMAN SACHS GROUP INC (3,602,162 shares), Woodline Partners LP (2,382,522 shares), GEODE CAPITAL MANAGEMENT, LLC (2,224,076 shares), and JACOBS LEVY EQUITY MANAGEMENT, INC (1,994,852 shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.